Striking a balance between medical device security and innovation. View as Webpage
Enable remote care. Break the boundaries that separate remote healthcare teams. >>
 
 
 
Subscribe
 
 
 
March 31, 2020
 
Fitbit_Charge_4_Full_Accessory_Collection
 
 

Fitbit has announced the latest member of its fitness tracker lineup, the Fitbit Charge 4, alongside new fitness-minded features and new content for Fitbit Premium.

The new device's standout feature is onboard GPS to enable features like an exercise heat map, which helps users review where in a running or biking route they were working the hardest.

It returns with the Sp02 sensor of its predecessor to enable sleep monitoring via nightly Sleep Scores, and will soon be updated with a sleep-cycle-based smart alarm that has so far only been included with the company's smartwatch offerings. Meanwhile, female health tracking, move reminders, food and water logging, automatic exercise tracking and a number of other standard Fitbit trackers functionalities all make a return.

Of particular note is that this device will be the first to support a new workout feature the company has dubbed Active Zone Minutes. With this, the device's heart-rate sensor will help determine when the wearer is in their own personal range of moderate or vigorous heart activity. The feature notifies the user of when they are shifting between these zones mid-workout. Afterward it will generate a report of the workout's zone time durations. It also calculates the minutes in each zone a user will need to meet their daily and weekly goals.

News of the new device and features comes with the announcement of new content additions for Fitbit's monthly subscription service. With it, Fitbit Premium has bumped its guided program count to 16. It includes more than 200 workouts from fitness brands such as barre3, Down Dog and Physique 57, and it will be looking to convert newcomers via a 90-day free trial supported by 40 pieces of new free content.

The Charge 4 will retail for $149.95 in the U.S., with a special edition running for $169.95.

WHY IT MATTERS

Both Fitbit and the broader wearables market have shifted toward a primary focus on smartwatches within the last few years. However, there's still a place for dedicated fitness trackers like the Charge devices, particularly among health-plan- or employer-sponsored wellness programs. Case in point: Today's announcement includes a note from Fitbit that the new tracker will be added later this year to UnitedHealthcare Motion, a wellness program in which participants can earn wearables through regular activity.

At the same time, Fitbit is continuing to support Fitbit Premium as the subscription service marches toward its one-year anniversary. This shouldn't be much of a surprise, as the company has signaled since its launch an interest in transitioning from episodic device sales to long-term, device-supported services.

THE LARGER TREND

All eyes were on Fitbit when rumors of an impending sale came to fruition late last year. But while the industry waits to see whether or not COVID-19, the Department of Justice or other factors will impede Google's purchase, the company has steadily fleshed out its offerings – November came with an OS update sporting heart-rate and sleep-tracking features, while January saw the activation of blood oxygen level variability measurements for Sp02-enabled devices.

 
medbelle
 
 
Photo Credit: Medbelle

Digital hospital Medbelle has announced it will be selling COVID-19 test kits to private patients at cost in an attempt to aid the NHS in its efforts to better understand the virus and to expand testing capabilities in the UK.

The kits cost £225 each, inclusive of laboratory, packaging and advisor fees. Purchases are limited to two per household to control demand, but the organization has an option for customers to “sponsor” up to 10 tests, which will then be distributed to vulnerable individuals or key workers free of charge.

Medbelle is encouraging those in need to apply for these free tests.

WHY IT MATTERS

The at-home test kits supplied by the startup follow the RT-PCR method recommended by the World Health Organization (WHO), that confirms whether a patient currently has coronavirus. It is not the same as the at-home antibody tests which are being developed.

The test involves taking a mucus sample from the nose and mouth, which the customer will self-swab and send off to a testing laboratory. It takes at least three days for the results to be processed and sent out to the patient by encrypted email.

Public Health England (PHE) and the patient’s GP are also notified of the results.

As the tests are processed in testing facilities not available to the NHS, Medbelle believes that offering private tests increases the country’s potential to gather information on COVID-19 without jeopardizing public testing capacities, which could ultimately save the NHS both time and money.

In a statement, Medbelle cited that the limited testing capacity of the NHS was not just down to laboratory availability but also logistical and financial restrictions, which the organization believes it can help combat through private testing. The report continued: “in future, should the NHS need our laboratory capacity or testing supplies, we would immediately pause or stop our service.”

THE LARGER PICTURE

In line with WHO recommendations to “test, test, test”, the UK is trying to increase its testing capabilities, with the hope of testing 25,000 cases per day by the end of April. However, stretched resources mean they have fallen short of their initial target of 10,000 per day, in spite of claiming to have the capacities to do so. This has been unfavorably compared to Germany where they are testing 500,000 people per week and their death rate is less severe.

In an effort to ease these pressures, Medbelle has already provided free tests for surgeons redeployed to the NHS and other clinical partners. In a statement, the company claimed: “we would prefer to make the test kits available at this price rather than delay and wait for a lower price,” promising to lower the cost if the market changes.

ON THE RECORD

Medbelle founder Leander de Laporte explained the motivation behind this decision in a statement: “To fight COVID-19 effectively, we need more tests to understand how the disease spreads and which measures we need to take. We are not doing this to make a profit; we want to do our best to support the NHS in these difficult times; to expand testing capacity and thereby add critical resources where they are needed.”

 
 
ADVERTISEMENT
Cisco
 
 
 
The AI company now has a presence among more than 500 U.S. hospitals.

Keep Reading >>
 
 
 
Marianna Imenokhoeva, founder at LinktoMedicine and Future50 International, writes about telehealth and its practicalities during the coronavirus pandemic.

Keep Reading >>
 
 
 
The round was led by Cigna Ventures and MemorialCare Innovation Fund with participation from Avalon Ventures, CU Healthcare Innovation Fund and Stanford Health Care.

Keep Reading >>
 
 
 
The medtech company has obtained provisional authorization from Singapore’s HSA for its rapid test kit to be used in Singapore.

Keep Reading >>
 
 
 
The weaknesses highlighted by the FDA in Urgent/11 demonstrate there are susceptibilities within software platforms that are both identifiable and resolvable.

Keep Reading >>
 
 
 
How is the coronavirus pandemic affecting you?
 
 
By HIMSS Insights
 
There is a renaissance of wearables in digital healthcare. More and more of them, many AI-empowered, are finding their way into serious clinical trials, thus contributing to medical evidence and ultimately better patient care. But with data comes responsibility: The question of how to design a digital healthcare data space that respects the privacy of individuals while at the same time providing maximal medical benefit is more important than ever.

Download the ebook now >>
 
 
ADVERTISEMENT
HIMSS TV
 
Technology Optimization Best Practices
 
What you need to know
 
This 18-part feature story series offers a deep dive into how CIOs and other healthcare leaders can best optimize technologies to produce results specific to a provider organization’s clinical and business needs.
 
 
 
 
 
2 Monument Sq., Ste 400 Portland, ME 04101
 
 
.